CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis
- PMID: 21562823
- DOI: 10.1007/s00894-011-1105-5
CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis
Abstract
Three dimensional pharmacophoric maps were generated for each isoforms of CYP2C9, CYP2D6 and CYP3A4 separately using independent training sets consist of highly potent substrates (seven substrates for each isoform). HipHop module of CATALYST software was used in the generation of pharmacophore models. The best pharmacophore model was chosen out of the several models on the basis of (i) highest ranking score, (ii) better fit value among training set, (iii) capability to screen substrates from data set and (iv) efficiency to identify the isoform specificity. The individual pharmacophore models (CYP2C9-hypo1, CYP2D6-hypo1 and CYP3A4-hypo1) are characterized by the pharmacophoric features XZDH, RPZH and XYZHH for the CYP2C9, CYP2D6 and CYP3A4 respectively. Each of the chosen models was validated by using data sets of CYP substrates. This comparative study of CYP substrates demonstrates the importance of acidic character along with HBD and HBAl features for CYP2C9, basic character with ring aromatic features for CYP2D6 and hydrophobic features for CYP3A4. Acidity, basicity and hydrophobicity features arising from the functional groups of the substrates are also responsible for demonstrating CYP isoform specificity. Hence, these chemical features are incorporated in the decision tree along with pharmacophore maps. Finally, a decision tree based on chemical features and pharmacophore features was generated to identify the isoform specificity of novel query molecule toward the three isoforms.
Similar articles
-
Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. J Pharmacol Exp Ther. 1999. PMID: 10490933
-
Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop.Comb Chem High Throughput Screen. 2011 Nov;14(9):811-23. doi: 10.2174/138620711796957170. Comb Chem High Throughput Screen. 2011. PMID: 21605066
-
In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.J Ethnopharmacol. 2010 Jul 20;130(2):275-83. doi: 10.1016/j.jep.2010.05.002. Epub 2010 May 8. J Ethnopharmacol. 2010. PMID: 20457244
-
Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling.Drug Metab Rev. 2012 Feb;44(1):1-17. doi: 10.3109/03602532.2011.645581. Drug Metab Rev. 2012. PMID: 22242930 Review.
-
New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.Curr Drug Metab. 2009 Dec;10(10):1075-126. doi: 10.2174/138920009790820129. Curr Drug Metab. 2009. PMID: 20167001 Review.
Cited by
-
The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters.mBio. 2022 Apr 26;13(2):e0370521. doi: 10.1128/mbio.03705-21. Epub 2022 Mar 1. mBio. 2022. PMID: 35229634 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
